|
1
|
Botter SM, Neri D and Fuchs B: Recent
advances in osteosarcoma. Curr Opin Pharmacol. 16:15–23. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin PP and Patel S: OsteosarcomaBone
Sarcoma. Springer; New York, NY: pp. 75–97. 2013, View Article : Google Scholar
|
|
3
|
Moore DD and Luu HH:
OsteosarcomaOrthopaedic Oncology. Springer; New York, NY: pp.
65–92. 2014
|
|
4
|
Akiyama T, Dass CR and Choong PF: Novel
therapeutic strategy for osteosarcoma targeting osteoclast
differentiation, bone-resorbing activity, and apoptosis pathway.
Mol Cancer Ther. 7:3461–3469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Esteller M: Non-coding RNAs in human
disease. Nat Rev Genet. 12:861–874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perkel JM: Visiting ‘noncodarnia’.
Biotechniques. 54:3012013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ning S, Zhang J, Wang P, Zhi H, Wang J,
Liu Y, Gao Y, Guo M, Yue M, Wang L and Li X: Lnc2Cancer: A manually
curated database of experimentally supported lncRNAs associated
with various human cancers. Nucleic Acids Res. 44:D980–D985. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Augoff K, McCue B, Plow EF and
Sossey-Alaoui K: miR-31 and its host gene lncRNA LOC554202 are
regulated by promoter hypermethylation in triple-negative breast
cancer. Mol Cancer. 11:52012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Y, Li H, Hou S, Hu B, Liu J and Wang
J: The noncoding RNA expression profile and the effect of lncRNA
AK126698 on cisplatin resistance in non-small-cell lung cancer
cell. PLoS One. 8:e653092013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng HT, Shi DB, Wang YW, Li XX, Xu Y,
Tripathi P, Gu WL, Cai GX and Cai SJ: High expression of lncRNA
MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.
Int J Clin Exp Pathol. 7:3174–3181. 2014.PubMed/NCBI
|
|
11
|
Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J
and Fang G: Up-regulated long non-coding RNA H19 contributes to
proliferation of gastric cancer cells. FEBS J. 279:3159–3165. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu
J: Long non-coding RNA H19 increases bladder cancer metastasis by
associating with EZH2 and inhibiting E-cadherin expression. Cancer
Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chan LH, Wang W, Yeung W, Deng Y, Yuan P
and Mak KK: Hedgehog signaling induces osteosarcoma development
through Yap1 and H19 overexpression. Oncogene. 33:4857–4866. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun XH, Yang LB, Geng XL, Wang R and Zhang
ZC: Increased expression of lncRNA HULC indicates a poor prognosis
and promotes cell metastasis in osteosarcoma. Int J Clin Exp
Pathol. 8:2994–3000. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Q, Geng PL, Yin P, Wang XL, Jia JP
and Yao J: Down-regulation of long non-coding RNA TUG1 inhibits
osteosarcoma cell proliferation and promotes apoptosis. Asian Pac J
Cancer Prev. 14:2311–2315. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi Y, Wang Y, Luan W, Wang P, Tao T,
Zhang J, Qian J, Liu N and You Y: Long non-coding RNA H19 promotes
glioma cell invasion by deriving miR-675. PLoS One. 9:e862952014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lv J, Ma L, Chen XL, Huang XH and Wang Q:
Downregulation of LncRNAH19 and MiR-675 promotes migration and
invasion of human hepatocellular carcinoma cells through
AKT/GSK-3β/Cdc25A signaling pathway. J Huazhong Univ Sci Technolog
Med Sci. 34:363–369. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:862013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan JX: LncRNA H19 promotes
atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur
Rev Med Pharmacol Sci. 21:322–328. 2017.PubMed/NCBI
|
|
21
|
Hyam SR, Lee IA, Gu W, Kim KA, Jeong JJ,
Jang SE, Han MJ and Kim DH: Arctigenin ameliorates inflammation in
vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing
M1 macrophages to M2-like macrophages. Eur J Pharmacol. 708:21–29.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han W, Xiong Y, Li Y, Fang W, Ma Y, Liu L,
Li F and Zhu X: Anti-arthritic effects of clematichinenoside (AR-6)
on PI3K/Akt signaling pathway and TNF-α associated with
collagen-induced arthritis. Pharm Biol. 51:13–22. 2013. View Article : Google Scholar : PubMed/NCBI
|
